Site icon IAS Current Affairs

India’s Indigenous Antibiotic

India’s Indigenous Antibiotic

Source: Indian Express
GS III: Science and Technology – Developments and their applications and their effects in everyday life.


Overview

  1. News in brief
  2. Significance of the development
  3. What is Anti-Microbial Resistance (AMR)?
  4. Way Ahead

Why in the News?

Recently, the US FDA has approved Zaynich (Nafithromycin), an indigenously developed antibiotic in India.

News in Brief

  • The United States Food and Drug Administration approval for Zaynich marks a milestone for the Indian innovation ecosystem.
  • Zaynich (Brand name), Nafithromycin (Scientific name of the antibiotic): developed for Community – Acquired Bacterial Pneumonia (CABP).
  • This development helps to treat the global threat of Anti-Microbial Resistance (AMR).
Significance of the development

  • The first indigenously developed antibiotic in India.
  • It is regarded as India’s first major breakthrough in nearly three decades.
  • Addresses the fight against the toughest Anti-Microbial Resistance (AMR) challenges in the world.
  • Demonstrates India’s transition from producer of affordable medicines and vaccines to an innovator in antibiotics that meet the most demanding global standards.
  • Showcases Indian drug innovators’ capability in discovering and developing new therapeutics with global relevance on the global stage.
  • Ensured that Indian innovation can address global health challenges at the highest level.
  • Symbolises the maturation of the Indian life-Science ecosystem.

What is Anti-Microbial Resistance (AMR)?

  • Occurs when germs that cause infections resist the effectiveness of treatments and become harder to cure.
  • Driven by misuse and overuse of antibiotics.
  • The World Health Organisation considers AMR as one of the most serious threats to global health.
Way Ahead

  • Ensure the regulatory framework aligns with India’s innovation ambitions.
  • The Indian regulator, Central Drugs Standard Control Organisation (CDSCO) should accelerate approval for innovative antibiotics that address unmet medical needs.
  • Ensure no compromise is made in scientific rigour.
  • Strengthen antimicrobial stewardship.
  • Promote appropriate use of antimicrobial medicines to preserve their effectiveness and reduce the emergence of AMR.
  • Accelerated approval should thus be linked to appropriate stewardship measures, surveillance and post-marketing monitoring.
  • Ensure rapid, responsible and affordable access.
  • Collaborate with international organisations on AMR research for data sharing and the development of new antimicrobial agents.

Daily Current Affairs: Click Here

Rate this Article and Leave Feedback
Exit mobile version